Advanced Search

National Health Act 1953 - Amendment determination under paragraph 98C(1)(b) - conditions (No. PB 38 of 2012)

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now for only USD$40 per month.
 
COMMONWEALTH OF AUSTRALIA
Instrument number PB 38 of 2012
Amendment determination under paragraph 98C(1)(b) of the National Health Act 19531
 
I, Felicity McNeill, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this instrument under paragraph 98C(1)(b) of the National Health Act 1953.
 
Dated                                          7 June 2012
 
 
 
 
 
 
 
 
FELICITY McNEILL
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing
Amendment determination — conditions
1              Commencement                                                        
                This instrument commences on 1 July 2012.
2              Amendment of the Determination under paragraph 98C(1)(b) of the National Health Act 1953 (PB 119 of 2008)
                Schedule 1 amends the Determination under paragraph 98C(1)(b) of the National Health Act 1953 (PB 119 of 2008).
Schedule 1            Amendments
 
[1]        Schedule 3, entry for Fentanyl
omit:

 
Lozenges 200 micrograms (as citrate), 3

 
Lozenges 200 micrograms (as citrate), 30

 
Lozenges 400 micrograms (as citrate), 3

 
Lozenges 400 micrograms (as citrate), 30

 
Lozenges 600 micrograms (as citrate), 3

 
Lozenges 600 micrograms (as citrate), 30

 
Lozenges 800 micrograms (as citrate), 3

 
Lozenges 800 micrograms (as citrate), 30

 
Lozenges 1200 micrograms (as citrate), 3

 
Lozenges 1200 micrograms (as citrate), 30

 
Lozenges 1600 micrograms (as citrate), 3

 
Lozenges 1600 micrograms (as citrate), 30

substitute:

 
Lozenge 200 micrograms (as citrate)

 
Lozenge 400 micrograms (as citrate)

 
Lozenge 600 micrograms (as citrate)

 
Lozenge 800 micrograms (as citrate)

 
Lozenge 1200 micrograms (as citrate)

 
Lozenge 1600 micrograms (as citrate)

 
[2]        Schedule 4, omit entry for Dabigatran etexilate
[3]        Schedule 4, after entry for Glucose Indicator—Blood in the form Test strips, 100 (Accu-Chek Performa)
insert:
 
Test Strips, 100 (BGStar)
 
[4]        Schedule 4, omit entry for Rivaroxaban
 
 
 
 
 
 
 
 
 
 
1Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. 
See http://www.frli.gov.au.